Jithma Abeykoon, M.D.
@JithmaA
Assistant Professor in Hematology and Medical Oncology at Mayo Clinic, MN, USA. Tweets are my own.
This is the kind of ground-breaking research by scientists and doctors that is being gutted right now: cancerblog.mayoclinic.org/2022/09/14/the…
🔁 Re-sharing a study from our group on long-term outcomes in adult LCH 🧬 Clinical phenotypes, treatment patterns, and prognostic factors 📊 219 adults | ↑ mortality vs general population esp. among <55y and multi-system disease 🔗 tinyurl.com/yvdry9ms #LCH #RareDiseases
And now into the head and neck region. As expected, Dr. Katharine Price delivers an outstanding presentation on advances in head and neck cancer including KN-689. But who really benefits…? @MayoMedEd @MayoCancerCare @MayoHemeOnc
Our findings are important and open a new understanding of biology and novel way of therapy @MayoCancerCare @WitzigLab JCI - Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma jci.org/articles/view/…
Redefining risk stratification in pLCH sciencedirect.com/science/articl… This is a significant study that redefines risk stratification in pediatric LCH. @ECDGA @HistiocyteSoc @MayoCancerCare
Just online! Thrilled to share our work on mesenchymal dendritic cells neoplasms with focus on distinction from Histiocytic & classical dendritic/Langerhans cell neoplasms #raredisdeaseawareness Incredible work by @dr_nehas and all co-authors @JithmaA @GauravGoyalMD
So proud and happy to share our review on mesenchymal dendritic cell neoplasms - untangling ontogeny, classification & diagnostic challenges in FDCS & FRCT !! mdpi.com/2072-6694/17/1… @aravindranmd thank you so much !! #PathTwitter #HemePath
Dr Ansell discussing plenary abstract ICML Lugano on predicting response to CART by microenvironment signature @MayoCancerCare
🚨 Our new study highlights how cell of origin + CNS-IPI scores can help predict CNS relapse in #DLBCL A step forward in better risk stratification that incorporates disease-biology. Presented @ASCO Read more in @ASHClinicalNews 👇 🔗 ashpublications.org/ashclinicalnew… #Lymphoma #CNSRelaps
Cell-of-origin as well as CNS-IPI were independently predictive of the risk for secondary #CNSlymphoma in #DLBCL, a finding that could give confidence to clinicians looking to assess the potential for this rare but serious complication #ASCO25: ow.ly/fwIL50W999O
Featured today by @MSKLibrary: Approach to the Patient: From Endocrinopathy to the Diagnosis of a Histiocytic Disorder dx.doi.org/10.1210/clinem… #Endocrinology #HistiocyticDisorders #RareDiseases #DiagnosticPathways #ClinicalEndocrinology #MultisystemDisorders #MedicalEducation…
Here is the group photo of the doctors who participated in the 2025 ECDGA Medical Symposium in Barcelona. erdheim-chester.org/medical-expert…
End of an era at @MayoHemeOnc fellowship! Thanks for vouching for us all along Dr. Hobday! We were fortunate to have trained under your aegis! Super excited for the amazing team of @jonaspaludo @UDuraniMD @BSiontis to lead the program to new heights!